InvestorsHub Logo
Followers 21
Posts 1400
Boards Moderated 0
Alias Born 03/03/2021

Re: hmuney post# 459871

Friday, 04/15/2022 9:24:48 AM

Friday, April 15, 2022 9:24:48 AM

Post# of 695348
Sweet, 'but' LL session is " Unique Challenges in Emerging Immunotherapies"... so, let's repeat, "challenges"... Don't fall for TLD assumption based on a discussions about challenges of something we are begging for...

I am super hopeful we can glean something new, but it certainly could be combo trial based info, or that outside of our NWBO universe, DC vaccines are not understood or accepted yet, hence Bosch's ASCO's title.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News